104 related articles for article (PubMed ID: 8898930)
1. Prognostic value of serum M-protein doubling time at escape from plateau of multiple myeloma. The Finnish Leukaemia Group.
Oivanen TM
Eur J Haematol; 1996 Sep; 57(3):247-53. PubMed ID: 8898930
[TBL] [Abstract][Full Text] [Related]
2. Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Finnish Leukaemia Group.
Oivanen TM
Br J Haematol; 1996 Mar; 92(4):834-9. PubMed ID: 8616075
[TBL] [Abstract][Full Text] [Related]
3. Posttreatment nadir M-protein level is a stronger discriminator of survival following plateau attainment than is percent reduction in M-protein in patients with IgG myeloma.
Shimizu K; Nagura E; Hirabayashi N; Wakita A; Takeyama H; Sao H; Nitta M; Kawashima K; Saito H
Int J Hematol; 2001 Aug; 74(2):205-8. PubMed ID: 11594523
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival in multiple myeloma: a Finnish Leukaemia Group study.
Br J Haematol; 1999 Jun; 105(4):942-7. PubMed ID: 10554804
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
6. Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group.
Shimizu K; Kamiya O; Hirabayashi N; Ichikawa A; Kawashima K; Kobayashi M; Mizuno H; Nagura E; Nitta M; Saito H; Sao H; Shibata T; Takeyama H
Jpn J Cancer Res; 1999 Mar; 90(3):355-60. PubMed ID: 10359052
[TBL] [Abstract][Full Text] [Related]
7. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
8. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
[TBL] [Abstract][Full Text] [Related]
9. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
10. Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy.
Corso A; Nozza A; Lazzarino M; Klersy C; Zappasodi P; Arcaini L; Bernasconi C
Haematologica; 1999 Apr; 84(4):336-41. PubMed ID: 10190948
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
Yakoub-Agha I; Attal M; Dumontet C; Delannoy V; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux V; Bay JO; Monconduit M; Harousseau JL; Duguet C; Duhamel A; Facon T
Hematol J; 2002; 3(4):185-92. PubMed ID: 12189564
[TBL] [Abstract][Full Text] [Related]
12. Clinical course and prognosis of non-secretory multiple myeloma.
Chawla SS; Kumar SK; Dispenzieri A; Greenberg AJ; Larson DR; Kyle RA; Lacy MQ; Gertz MA; Rajkumar SV
Eur J Haematol; 2015 Jul; 95(1):57-64. PubMed ID: 25382589
[TBL] [Abstract][Full Text] [Related]
13. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
14. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.
Ludwig H; Milosavljevic D; Berlanga O; Zojer N; Hübl W; Fritz V; Harding S
Am J Hematol; 2016 Mar; 91(3):295-301. PubMed ID: 26662888
[TBL] [Abstract][Full Text] [Related]
15. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
16. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone.
Wilder RB; Ha CS; Cox JD; Weber D; Delasalle K; Alexanian R
Cancer; 2002 Mar; 94(5):1532-7. PubMed ID: 11920511
[TBL] [Abstract][Full Text] [Related]
17. MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. MRC Working Party on Leukaemia in Adults.
Drayson MT; Chapman CE; Dunn JA; Olujohungbe AB; Maclennan IC
Br J Haematol; 1998 Apr; 101(1):195-202. PubMed ID: 9576201
[TBL] [Abstract][Full Text] [Related]
18. Response rate and survival after conventional chemotherapy for multiple myeloma by hospitals with different inclusion rates of patients to the trials. A Finnish Leukemia Group study.
Oivanen T; Kellokumpu-Lehtinen P; Koivisto AM; Koivunen E
Eur J Haematol; 1999 Oct; 63(4):225-30. PubMed ID: 10530410
[TBL] [Abstract][Full Text] [Related]
19. Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma.
Schaefer EW; Kumar S; Dispenzieri A; Allred JB; Gertz MA; Lacy MQ; Rajkumar SV; Mandrekar SJ
Cancer; 2010 Feb; 116(3):640-6. PubMed ID: 19924791
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of response or escape to chemotherapy and of survival of patients with multiple myeloma. A prospective study of 202 patients (1975-1982).
Bataille R; Souteyrand P; Sany J
Anticancer Res; 1984; 4(6):339-45. PubMed ID: 6517530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
